{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T14:14:27Z","timestamp":1783779267895,"version":"3.55.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"23","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Live vaccines are generally contraindicated in patients treated with biological agents. However, they are often needed in this patient population. This prospective study aimed to evaluate the immunogenicity and safety of the live attenuated varicella vaccine in patients receiving tumor necrosis factor-alpha (TNF-\u03b1) inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This single-center, prospective study was conducted at the National Center for Child Health and Development and registered with the Japan Registry of Clinical Trials in accordance with the Japanese Clinical Trials Act. Patients receiving TNF-\u03b1 inhibitors were enrolled. Those with varicella-specific immunoglobulin G (IgG) levels &lt;4.0 who also met predefined criteria of cellular and humoral immunity were eligible. A single dose of the varicella vaccine was administered, and varicella-specific IgG levels were measured before and after vaccination. Participants were monitored for adverse events for up to 6 months following vaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Ten pediatric patients (five with juvenile idiopathic arthritis and 5 with inflammatory bowel disease) were enrolled. Of these, 5 achieved seroconversion (defined as a varicella-specific IgG level of 4.0 or more) after a single vaccination (seroconversion rate: 50%). Three patients received a booster vaccination, and 1 subsequently achieved seroconversion. Adverse events were nonspecific, and none were related to the varicella vaccine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The varicella vaccine may be acceptable in patients receiving TNF-\u03b1 inhibitors. However, due to the small sample size, neither the efficacy nor safety can be definitively established in this pilot study. A larger-scale study is warranted to further evaluate immunogenicity and safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049103","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T04:01:32Z","timestamp":1780718492000},"page":"e49103","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Live attenuated varicella vaccines in patients treated with tumor necrosis factor-alpha inhibitors: A clinical trial"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3528-6961","authenticated-orcid":false,"given":"Koichi","family":"Kamei","sequence":"first","affiliation":[{"name":"Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Ogura","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, National Center for Child Health and Development, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, National Center for Child Health and Development, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiro","family":"Arai","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, National Center for Child Health and Development, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Shoji","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, National Center for Child Health and Development, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinao","family":"Kawai","sequence":"additional","affiliation":[{"name":"Department of Immunology, National Center for Child Health and Development, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Miyairi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hamamatsu University School of Medicine, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Murashima","sequence":"additional","affiliation":[{"name":"Division of Maternal Medicine, National Center for Child Health and Development, Tokyo, Japan"},{"name":"Japan Drug Information in Pregnancy Society, Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikara","family":"Ogimi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, National Center for Child Health and Development, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260711","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.cytogfr.2014.07.016","article-title":"TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants \u2013 past, present and future.","volume":"25","author":"Sedger","year":"2014","journal-title":"Cytokine Growth Factor Rev"},{"key":"R2-20260711","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1093\/cid\/ciz1138","article-title":"Tuberculosis disease in children and adolescents on therapy with antitumor necrosis factor-\u0251agents: a collaborative, multicenter Paediatric Tuberculosis Network European Trials Group (PTBNET) study.","volume":"71","author":"Noguera-Julian","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R3-20260711","doi-asserted-by":"crossref","first-page":"6473","DOI":"10.1038\/s41598-017-06899-1","article-title":"Active tuberculosis incidence and characteristics in patients treated with tumor necrosis factor antagonists according to latent tuberculosis infection.","volume":"7","author":"Lee","year":"2017","journal-title":"Sci Rep"},{"key":"R4-20260711","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1086\/421494","article-title":"Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor.","volume":"39","author":"Mohan","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R5-20260711","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.crohns.2010.05.001","article-title":"Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn\u2019s disease.","volume":"4","author":"Cheent","year":"2010","journal-title":"J Crohns Colitis"},{"key":"R6-20260711","doi-asserted-by":"crossref","first-page":"e242","DOI":"10.1097\/INF.0000000000002712","article-title":"Bacillus Calmette-Gu\u00e9rin cervical lymphadenitis in a 6-year-old boy on infliximab for inflammatory bowel disease.","volume":"39","author":"Yoshida","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"R8-20260711","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R9-20260711","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis.","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 2","key":"R10-20260711","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.cmi.2017.12.025","article-title":"ESCMID study group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (soluble immune effector molecules [I]: anti-tumor necrosis factor-\u03b1 agents).","volume":"24","author":"Baddley","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"R11-20260711","doi-asserted-by":"crossref","first-page":"e001041","DOI":"10.1136\/rmdopen-2019-001041","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases.","volume":"5","author":"Furer","year":"2019","journal-title":"RMD Open"},{"key":"R12-20260711","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s00431-021-03927-1","article-title":"Live attenuated vaccines under immunosuppressive agents or biological agents: survey and clinical data from Japan.","volume":"180","author":"Kamei","year":"2021","journal-title":"Eur J Pediatr"},{"key":"R13-20260711","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1086\/589862","article-title":"Vaccines: correlates of vaccine-induced immunity.","volume":"47","author":"Plotkin","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R14-20260711","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jpeds.2017.12.061","article-title":"Prospective study of live attenuated vaccines for patients with nephrotic syndrome receiving immunosuppressive agents.","volume":"196","author":"Kamei","year":"2018","journal-title":"J Pediatr"},{"key":"R15-20260711","doi-asserted-by":"crossref","first-page":"e0240217","DOI":"10.1371\/journal.pone.0240217","article-title":"Prospective study of live attenuated vaccines for patients receiving immunosuppressive agents.","volume":"15","author":"Kamei","year":"2020","journal-title":"PLoS One"},{"key":"R16-20260711","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1136\/ard.2006.063586","article-title":"Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis.","volume":"66","author":"Heijstek","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R17-20260711","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/rheumatology\/ken436","article-title":"Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept.","volume":"48","author":"Borte","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"R18-20260711","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/MPG.0b013e3181bab351","article-title":"Varicella vaccination in children with inflammatory bowel disease receiving immunosuppressive therapy.","volume":"50","author":"Lu","year":"2010","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R19-20260711","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/acr.20045","article-title":"Yellow fever revaccination during infliximab therapy.","volume":"62","author":"Scheinberg","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R20-20260711","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1756-185X.2010.01466.x","article-title":"Live polio vaccine exposure while receiving anti-TNF therapy for reactive arthritis.","volume":"13","author":"Badsha","year":"2010","journal-title":"Int J Rheum Dis"},{"key":"R21-20260711","doi-asserted-by":"crossref","first-page":"R174","DOI":"10.1186\/ar3497","article-title":"The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study.","volume":"13","author":"Zhang","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"R22-20260711","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.2012.7304","article-title":"Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases.","volume":"308","author":"Zhang","year":"2012","journal-title":"JAMA"},{"key":"R23-20260711","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1001\/jama.2013.6768","article-title":"Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: a randomized trial.","volume":"309","author":"Heijstek","year":"2013","journal-title":"JAMA"},{"key":"R24-20260711","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1016\/j.vaccine.2015.06.086","article-title":"Long-term safety and efficacy of varicella vaccination in children with juvenile idiopathic arthritis treated with biologic therapy.","volume":"33","author":"Toplak","year":"2015","journal-title":"Vaccine"},{"key":"R25-20260711","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/jtm.12209","article-title":"Yellow fever vaccination of a primary vaccinee during adalimumab therapy.","volume":"22","author":"Nash","year":"2015","journal-title":"J Travel Med"},{"key":"R26-20260711","doi-asserted-by":"crossref","first-page":"bcr2016215403","DOI":"10.1136\/bcr-2016-215403","article-title":"Inadvertent yellow fever vaccination of a patient with Crohn\u2019s disease treated with infliximab and methotrexate.","volume":"2016","author":"Ekenberg","year":"2016","journal-title":"BMJ Case Rep"},{"key":"R27-20260711","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1055\/s-0042-109871","article-title":"Yellow fever vaccination during treatment with infliximab in a patient with ulcerative colitis: a case report.","volume":"54","author":"R\u00fcddel","year":"2016","journal-title":"Z Gastroenterol"},{"key":"R28-20260711","doi-asserted-by":"crossref","first-page":"tax082","DOI":"10.1093\/jtm\/tax082","article-title":"Safety of live vaccines on immunosuppressive or immunomodulatory therapy-a retrospective study in three Swiss Travel Clinics.","volume":"25","author":"Huber","year":"2018","journal-title":"J Travel Med"},{"key":"R29-20260711","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1016\/j.vaccine.2017.04.015","article-title":"Varicella vaccination elicits a humoral and cellular response in children with rheumatic diseases using immune suppressive treatment.","volume":"35","author":"Groot","year":"2017","journal-title":"Vaccine"},{"key":"R30-20260711","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12969-018-0231-3","article-title":"Varicella-zoster-virus vaccination in immunosuppressed children with rheumatic diseases using a pre-vaccination check list.","volume":"16","author":"Speth","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"key":"R31-20260711","doi-asserted-by":"crossref","first-page":"8024","DOI":"10.1016\/j.vaccine.2020.10.028","article-title":"Varicella-zoster-virus vaccination of immunosuppressed children with inflammatory bowel disease or autoimmune hepatitis: a prospective observational study.","volume":"38","author":"Seitel","year":"2020","journal-title":"Vaccine"},{"key":"R32-20260711","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.7326\/M20-6928","article-title":"The safety and immunologic effectiveness of the live varicella-zoster vaccine in patients receiving tumor necrosis factor inhibitor therapy: a randomized controlled trial.","volume":"174","author":"Curtis","year":"2021","journal-title":"Ann Intern Med"},{"key":"R33-20260711","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijwd.2019.11.003","article-title":"Art of prevention: our approach to the measles-mumps-rubella vaccine in adult patients vaccinated against measles before 1968 on biologic therapy for the treatment of psoriasis.","volume":"6","author":"Worth","year":"2019","journal-title":"Int J Womens Dermatol"},{"key":"R34-20260711","first-page":"1","article-title":"General recommendations on immunization - recommendations of the advisory committee on immunization practices (ACIP).","volume":"60","year":"2011","journal-title":"MMWR Recomm Rep"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000049103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T14:01:45Z","timestamp":1783778505000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000049103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":33,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049103","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"2024-12-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}